US 12,173,320 B2
Production of red blood cells and platelets from stem cells
George J. Murphy, Boston, MA (US); David H. Sherr, West Roxbury, MA (US); Sarah S. Rozelle, Jamaica Plain, MA (US); and Brenden W. Smith, Warwick, RI (US)
Assigned to BOSTON MEDICAL CENTER CORPORATION, Boston, MA (US); and TRUSTEES OF BOSTON UNIVERSITY, Boston, MA (US)
Filed by BOSTON MEDICAL CENTER CORPORATION, Boston, MA (US); and TRUSTEES OF BOSTON UNIVERSITY, Boston, MA (US)
Filed on Aug. 20, 2021, as Appl. No. 17/407,349.
Application 15/898,526 is a division of application No. 14/421,191, granted, now 9,896,660, issued on Feb. 20, 2018, previously published as PCT/US2013/055160, filed on Aug. 15, 2013.
Application 17/407,349 is a continuation of application No. 15/898,526, filed on Feb. 17, 2018, granted, now 11,124,769.
Application 14/421,191 is a continuation in part of application No. 13/828,357, filed on Mar. 14, 2013, granted, now 9,074,186, issued on Jul. 7, 2015.
Claims priority of provisional application 61/683,246, filed on Aug. 15, 2012.
Prior Publication US 2022/0177845 A1, Jun. 9, 2022
Int. Cl. C12N 5/0789 (2010.01); A61K 31/404 (2006.01); A61K 31/655 (2006.01); A61K 35/18 (2015.01); A61K 35/19 (2015.01); A61K 45/06 (2006.01); C12N 5/078 (2010.01); G01N 33/50 (2006.01); G01N 33/80 (2006.01); G01N 33/86 (2006.01); A61K 35/12 (2015.01)
CPC C12N 5/0647 (2013.01) [A61K 31/404 (2013.01); A61K 31/655 (2013.01); A61K 35/18 (2013.01); A61K 35/19 (2013.01); A61K 45/06 (2013.01); C12N 5/0641 (2013.01); C12N 5/0644 (2013.01); G01N 33/5044 (2013.01); G01N 33/80 (2013.01); G01N 33/86 (2013.01); A61K 2035/124 (2013.01); C12N 2501/60 (2013.01); C12N 2501/998 (2013.01); C12N 2501/999 (2013.01); C12N 2506/03 (2013.01); C12N 2506/45 (2013.01); G01N 2500/10 (2013.01)] 3 Claims
 
1. A method of making a megakaryocyte (Mk), comprising:
obtaining a population of megakaryocyte-erythroid progenitor cells (MEP), and
culturing the population of MEP cells in the presence of an aryl hydrocarbon receptor (AhR) agonist prior to culturing the population of MEP cells in the presence of an aryl hydrocarbon receptor (AhR) antagonist to make a Mk,
wherein the population of MEP cells are differentiated from MEP precursor cells by culturing in the presence of an aryl hydrocarbon receptor (AhR) antagonist.